Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...
Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
Clinical outcomes for ulcerative colitis patients with a prior anti-TNF therapy failure appeared similar with ustekinumab ...
A study revealed that IBD patients, particularly those with ulcerative colitis and multiple biologic treatments, face an ...
Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on ...
Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.
Ulcerative colitis is a chronic, immune-mediated disorder of the colon and rectum characterized by mucosal inflammation that damages the bowel wall surface. Current therapeutic options include ...
In a mid-stage study, the candidate itolizumab achieved 23.3% clinical remission rate at 12 weeks, numerically better than ...
The composite of patient-reported clinical response and endoscopic response was significantly greater in mirikizumab versus ...
Mirikizumab showed superior maintenance efficacy over most treatments for ulcerative colitis (UC), according to a network ...
Equillium, Inc. (NASDAQ:EQ), a biotechnology company with a market capitalization of $25.15 million and current stock price of $0.71, announced today the positive outcomes of their Phase 2 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback